Forest
Actavis to axe 200 jobs
December 4, 2014Medical Communications, Sales and Marketing Actavis, Allergan, Forest, GSK, Warner Chilcott, corona, stevenage
Actavis is set to cut 200 jobs in the US just weeks after buying Allergan for $66 billion. The lay-offs …
Allergan and Valeant trade blows as shareholder meeting looms
November 6, 2014Sales and Marketing Actavis, Allergan, Forest, Valeant, merger, warner
Allergan’s efforts to block a key supporter of Valeant’s hostile takeover bid from voting at next month’s special shareholder meeting …
Forest sold to Actavis for $25 billion
February 18, 2014Sales and Marketing Actavis, CNS, Forest, acquisition, labs, merger, synergy
The rumours of a substantial deal for Forest have been proven true after Actavis announced this afternoon that it will …
Forest to buy Aptalis for $2.9 billion
January 9, 2014Sales and Marketing Forest, aptlias, canasa, maris
Forest Laboratories will spend around $2.9 billion to purchase Aptalis, a privately-held US firm specialising in treatments for gastrointestinal disorders …
FDA approves Forest’s COPD drug
July 25, 2012Sales and Marketing COPD, FDA, Forest, Tudorza Pressair
US regulators have approved Forest Laboratories’ new chronic obstructive pulmonary disease (COPD) drug. Tudorza Pressair (aclidinium bromide) has been given …
Forest’s COPD drug approved in US
March 3, 2011Sales and Marketing COPD, Daliresp, Daxas, Forest, Forest Laboratories, chronic obstructive pulmonary disease, roflumilast
Daliresp (roflumilast) has been approved by the FDA to treat severe chronic obstructive pulmonary disease. Forest Laboratories’ once-daily pill is …
Forest depression candidate struggles against placebo
March 1, 2011Research and Development Forest, Forest Laboratories, Gedeon Richter, cariprazine, depression, major depressive disorder
An investigational antipsychotic drug being developed by Forest Laboratories and Budapest-based Gedeon Richter has failed to prove itself in phase …
Almirall and Forest’s phase III COPD drug misses goal
November 3, 2010Research and Development Aclidinium bromide, Almirall, COPY, Forest, Forest Laboratories, chronic obstructive pulmonary disease
Almirall and Forest’s COPD drug aclidinium bromide has disappointed in a phase III trial by producing fewer benefits than found …
AstraZeneca signs deals to increase anti-infective portfolio
January 7, 2010Research and Development, Sales and Marketing AstraZeneca, Forest, Novexel
AstraZeneca is to buy infection research firm Novexel for $350 million. The manufacturer will take all the French company’s shares …
AZ signs antibiotic deal with Forest Laboratories
August 13, 2009Research and Development, Sales and Marketing Antibiotics, Forest
AstraZeneca has struck a deal with Forest Laboratories to co-develop and commercialise ceftaroline, an anti-infective drug in phase III. The …
